Zacks Investment Research lowered shares of Dermira (NASDAQ:DERM) from a hold rating to a sell rating in a research report report published on Thursday.
According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “
Several other research analysts have also recently weighed in on the stock. BidaskClub upgraded shares of Dermira from a hold rating to a buy rating in a report on Tuesday, January 30th. Cantor Fitzgerald set a $45.00 price target on shares of Dermira and gave the stock a buy rating in a report on Monday, January 15th. Guggenheim restated a buy rating and set a $30.00 price target on shares of Dermira in a report on Thursday, December 14th. Mizuho cut their price target on shares of Dermira from $43.00 to $39.00 and set a buy rating on the stock in a report on Tuesday, December 12th. Finally, Cowen set a $25.00 price target on shares of Dermira and gave the stock a buy rating in a report on Monday, March 5th. Four analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of Hold and an average target price of $32.71.
Dermira (NASDAQ:DERM) last posted its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.25) by ($0.09). The business had revenue of $1.34 million for the quarter, compared to the consensus estimate of $1.10 million. Dermira had a negative return on equity of 62.07% and a negative net margin of 6,678.29%. research analysts anticipate that Dermira will post -4.66 EPS for the current year.
In related news, insider Eugene A. Bauer sold 3,000 shares of the business’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $28.55, for a total transaction of $85,650.00. Following the transaction, the insider now directly owns 5,802 shares in the company, valued at $165,647.10. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Thomas G. Wiggans sold 5,000 shares of the business’s stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $27.51, for a total transaction of $137,550.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 34,758 shares of company stock worth $948,029. 13.30% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quantbot Technologies LP boosted its stake in Dermira by 75.4% in the third quarter. Quantbot Technologies LP now owns 5,371 shares of the biopharmaceutical company’s stock valued at $145,000 after acquiring an additional 2,309 shares during the last quarter. Aperio Group LLC purchased a new position in Dermira in the fourth quarter valued at about $213,000. SG Americas Securities LLC boosted its stake in Dermira by 47.7% in the third quarter. SG Americas Securities LLC now owns 8,130 shares of the biopharmaceutical company’s stock valued at $220,000 after acquiring an additional 2,627 shares during the last quarter. Two Sigma Advisers LP purchased a new position in Dermira in the fourth quarter valued at about $222,000. Finally, Teacher Retirement System of Texas purchased a new position in Dermira in the fourth quarter valued at about $283,000. Hedge funds and other institutional investors own 94.67% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was published by Markets Daily and is the property of of Markets Daily. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.themarketsdaily.com/2018/03/12/dermira-derm-rating-lowered-to-sell-at-zacks-investment-research.html.
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.